Form D · Biotechnology
Hunterian Medicine LLC
Baltimore, MD · CIK 0001685325
Offering snapshot reported Sep 25, 2024 · SEC filing
- Reported sold
- $4.6M Indefinite offering
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Sep 11, 2016 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2024 | Amendment | $4,595,000 | $0vs Sep 21, 2023 | 26 | SEC filing |
| Sep 21, 2023 | Amendment | $4,595,000 | $450,000vs Sep 23, 2022 | 26 | SEC filing |
| Sep 23, 2022 | Amendment | $4,145,000 | $265,000vs Sep 17, 2021 | 23 | SEC filing |
| Sep 17, 2021 | Amendment | $3,880,000 | No comparison | Not reported | SEC filing |
| Sep 18, 2020 | Amendment | $3,480,000 | $350,000vs Sep 18, 2019 | 18 | SEC filing |
| Sep 18, 2019 | Amendment | $3,130,000 | $400,000vs Sep 18, 2018 | 16 | SEC filing |
| Sep 18, 2018 | Amendment | $2,730,000 | $650,000vs Sep 20, 2017 | 15 | SEC filing |
| Sep 20, 2017 | Amendment | $2,080,000 | $1,850,000vs Sep 23, 2016 | 13 | SEC filing |
| Sep 23, 2016 | Initial | $230,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-271156
Debt convertible to preferred securities.
Source: Form D, filed Sep 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vinod Jaskula Ranga | Director, Executive |
| Vinod Ranganathan | Director, Executive |
| James Akiva Silverglad | Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Baltimore, MD, 21215